Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Company Overview

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver.

Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6. The company has evaluated bexotegrast in clinical studies for idiopathic pulmonary fibrosis and is also studying its potential in other fibrotic conditions, including primary sclerosing cholangitis. Pliant has also developed additional preclinical and clinical-stage programs targeting integrin pathways and organ fibrosis.

Founded in 2015 and headquartered in South San Francisco, California, Pliant conducts research and clinical development activities through collaborations and clinical trials that can involve patients and investigators in multiple regions. The company became publicly traded in 2020. Pliant has been led by Bernard Coulie, M.D., Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $0.84 to $0.88
• 50-Day Range: $0.84 to $1.17
• 52-Week Range: $0.83 to $1.82
• Volume: 204,987 shs
• Average Volume: 379,278 shs
• Market Capitalization: $52.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Pliant Therapeutics Stock Analysis - MarketRank™

Pliant Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 780th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Pliant Therapeutics has a consensus price target of $3.00, representing about 252.2% upside from its current price of $0.85.

Amount of Analyst Coverage

Pliant Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.53) per share.

Price to Book Value per Share Ratio

Pliant Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.20% of the float of Pliant Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pliant Therapeutics has a short interest ratio ("days to cover") of 10.36, which indicates bearish sentiment.

Change versus previous month

Short interest in Pliant Therapeutics has recently increased by 9.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pliant Therapeutics does not currently pay a dividend.

Dividend Growth

Pliant Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.74% of the stock of Pliant Therapeutics is held by insiders.

Percentage Held by Institutions

97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PLRX
• CIK: 1746473
• Web: pliantrx.com
• Phone: 650-481-6770
• Fax: N/A
• Employees: 49
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Pliant Therapeutics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +252.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$149.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.17%
• Return on Assets: -40.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.90
• Quick Ratio: 9.90

Sales & Book Value

• Annual Sales: $1.58 million
• Price / Sales: 33.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.95 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 61,920,000
• Free Float: 56,510,000
• Market Cap: $52.74 million
• Optionable: Optionable
• Beta: 1.36